This observational neuroimaging study employs advanced imaging techniques to characterize brain changes in Progressive Supranuclear Palsy (PSP) and related Parkinsonian syndromes. The study addresses a critical gap in our understanding of how tau pathology manifests on different imaging modalities and how these findings correlate with clinical phenotypes[1].
Neuroimaging plays a pivotal role in the diagnosis and monitoring of atypical parkinsonism. Unlike Parkinson's Disease (PD), where dopaminergic degeneration is the primary finding, PSP and related disorders show distinct patterns of atrophy, metabolic changes, and network disruption that can be visualized with modern imaging techniques.
| Field | Value |
|---|---|
| NCT Number | NCT03872102 |
| Status | Recruiting |
| Study Type | Observational |
| Conditions | PSP, PD, MSA |
| Sponsor | French Research Consortium |
| Sites | Multiple centers in France |
| Enrollment Target | 200+ participants |
| Duration | 3-year study with longitudinal imaging |
Neuroimaging has evolved from a primarily exclusionary tool to a positive diagnostic modality in atypical parkinsonism. While conventional MRI remains useful for ruling out secondary causes, advanced techniques can now visualize the specific pathological changes that define each disorder.
The diagnosis of PSP has evolved with the recognition that multiple clinical phenotypes exist beyond the classic Richardson's syndrome. MRI findings vary substantially by subtype[2]:
Multiple PET tracers provide insights into the underlying pathology[4]:
| Tracer | Target | Findings in PSP |
|---|---|---|
| [^18F]FDG | Glucose metabolism | Hypometabolism in frontal cortex, brainstem, striatum |
| [^11C]PiB | Amyloid | Typically negative (distinguishes from AD) |
| [^18F]AV-1451 | Tau | Variable binding in basal ganglia, brainstem, cortical regions |
DTI reveals microstructural damage that often precedes visible atrophy[3:1]:
The field is moving toward integrated multimodal approaches:
The study employs comprehensive MRI protocols:
PET imaging provides molecular insights:
The study includes comprehensive clinical assessments:
Accurate neuroimaging provides critical benefits:
Imaging supports clinical diagnosis and can differentiate PSP from:
Advanced techniques may identify prodromal changes:
Imaging endpoints complement clinical measures in trials:
This study complements other neuroimaging initiatives:
Classic PSP shows characteristic imaging:
The parkinsonian variant shows:
Features of corticobasal syndrome with PSP:
The study aims to develop clinically applicable tools:
Validated imaging biomarkers will enable:
Neuroimaging for Parkinsonian Syndromes - ClinicalTrials.gov. ↩︎
Whitwell JL, et al. Magnetic resonance imaging in progressive supranuclear palsy. Movement Disorders. 2017. ↩︎
Bailey M, et al. Diffusion MRI in atypical parkinsonism. Parkinsonism and Related Disorders. 2013. ↩︎ ↩︎
Nicastro N, et al. Tau PET imaging in progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry. 2020. ↩︎
Höglinger GU, et al. Clinical diagnosis of progressive supranuclear palsy: The MDSPSP criteria. Movement Disorders. 2017. ↩︎